drugset / Trial / NCT07500987
Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC
NaSingle-groupOpen-labelDiagnostic
Summary
This is a Phase I, multicentre, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, PD, and PK of \[111In\]-FPI-2107 after pre-dose administration of FPI-2053 in Chinese participants with EGFR mutation-positive NSCLC.
Timeline
- Start
- 2026-02-27
- Primary completion
- 2026-07-21
- Completion
- 2026-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [111In]-FPI-2107 | Diagnostic / imaging agent | — | — |
| Background | FPI-2053 | Monoclonal antibody | — | — |
Indications
No indication recorded.